Please login to the form below

Not currently logged in

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

Johnson & Johnson (J&J) has revealed positive results demonstrating that its COVID-19 vaccine generated ‘strong, persistent’ activity against the highly transmissible Delta variant.

A pre-print paper, submitted to bioRxiv yesterday, includes analysis from blood samples taken from a group of participants in J&J’s phase 3 ENSEMBLE COVID-19 vaccine study.

According to the new data, J&J’s single-dose vaccine produced neutralising antibody activity against the Delta variant at a higher level than it had previously been shown to elicit against the Beta variant.

Data submitted to bioRxiv from a sub-study J&J’s phase 1/2a COVID-19 vaccine study showed that humoral and cellular immune responses generated by the jab lasted for at least eight months.

The pharma company added that a single dose of its COVID-19 vaccine generated neutralising antibodies against a range of SARS-CoV-2 variants of concerns, with these levels increasing over time.

“Current data for the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralising antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, global head, Janssen Research & Development, Johnson & Johnson.

“With each new data set, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health,” he added.

Earlier this week, Moderna announced that its COVID-19 vaccine showed promising activity against COVID-19 variants in lab studies, including the Delta variant.

According to Moderna, its mRNA-based vaccine showed activity against all variants tested, including the Beta variant first discovered in South Africa and the Delta variant.

A UK study previously found that two doses of either the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines are ‘highly effective’ against the Delta variant.

The vaccine produced neutralising titers against more recently identified variants, including the Eta variant which was first discovered in Nigeria and the A.23.1 and A.VOI.V2 variants first identified in Uganda and Angola, respectively.

According to the study led by Public Health England, after two doses either vaccine offer similar protection against the B.1.617.2 variant compared with the B.1.1.7 or Kent variant.

Article by
Lucy Parsons

2nd July 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...